Condition
HIV Infection
HIV is a virus that infects the immune system's CD4 cells, gradually weakening the body's defenses against other infections. Enfuvirtide has the strongest evidence, and a phase III trial found it lowered viral load more than an optimized background regimen alone at 24 weeks in people who had already tried other HIV medicines. Those results mostly apply to people with that history and to 24 weeks, so they say less about longer-term outcomes.
Sources: PMID 35672866
- Updated
- How we grade
- 34 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 5
Prescription medicines and peptides studied, for context
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Viral Load Reduction Phase III: Superior virological activity vs optimized background regimen alone at 24 weeks in treatment-experienced patients. | Improves (the measure goes down) | Large effect | 19 studies | |||
Studies that measured viral load reduction | ||||||
| CD4 Count Improvement Significant immunological improvement demonstrated in pivotal Phase III trials (TORO-1 and TORO-2). | Improves (the measure goes up) | Moderate effect | 19 studies | |||
Studies that measured cd4 count improvement | ||||||
| Treatment-Experienced Efficacy Effective in patients with documented resistance to NRTIs, NNRTIs, and PIs. Valuable rescue therapy option. | Improves (the measure goes up) | Large effect | 19 studies | |||
Studies that measured treatment-experienced efficacy | ||||||
| Viral Suppression Rate Higher proportion achieving viral suppression when added to optimized background therapy in clinical trials. | Improves (the measure goes up) | Moderate effect | 19 studies | |||
Studies that measured viral suppression rate | ||||||
| Time to Treatment Failure Prolonged time to virologic failure compared to control arm in Phase III studies. | Improves (the measure goes up) | Moderate effect | 19 studies | |||
Studies that measured time to treatment failure | ||||||
Key findings
- Viral Load ReductionImproves (the measure goes down)
- CD4 Count ImprovementImproves (the measure goes up)
- Treatment-Experienced EfficacyImproves (the measure goes up)
Studies cited
34 studies from PubMed
- Quality by Design-Guided Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Enfuvirtide.
- Transdermal delivery of enfuvirtide using dissolving microneedles integrated with novel insertion and removal indicator.
- Isopeptide Bond Bundling Superhelix for Designing Antivirals against Enveloped Viruses with Class I Fusion Proteins: A Review.
- Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.
- Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch.
- Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
- Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature.
- Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
- Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
- A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
- Enfuvirtide, the first fusion inhibitor to treat HIV infection
- Long-term efficacy and safety of enfuvirtide combined with an optimized background regimen
- Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
- Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
- Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
- Enfuvirtide: a review of its use in the management of HIV infection.
- Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection
- Resistance to enfuvirtide, the first HIV fusion inhibitor
- Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
- [Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].
- [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
- Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development
- Enfuvirtide: a fusion inhibitor for the treatment of HIV infection
- Enfuvirtide: first fusion inhibitor for treatment of HIV infection
- Enfuvirtide: the first HIV fusion inhibitor
- Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
- Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
- Enfuvirtide (T-20): a new drug in the treatment of HIV infection
- Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
- Fuzeon data review.
- Clinical trials for enfuvirtide (Fuzeon, T-20).
- Antiviral drugs with extra-cellular sites of action.
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
- Pentafuside effective.